Search

Displaying results 3181 - 3190 of 4860 in total
  1. Drug

    Phylloquinone

    go.drugbank.com/drugs/DB01022
    ApprovedInvestigational

    [A234264,A234195,A234259] It is indicated in the treatment of coagulation disorders due to faulty formation of coagulation factors II, VII, IX, and X caused by deficiency or interference in the activity

  2. Drug

    Thalidomide

    go.drugbank.com/drugs/DB01041
    ApprovedInvestigationalWithdrawn

    It has been reintroduced and used for a number of inflammatory disorders and cancers.

  3. Drug

    Fluvastatin

    go.drugbank.com/drugs/DB01095
    ApprovedInvestigational

    It is also the first entirely synthetic HMG-CoA reductase inhibitor and is structurally distinct from the fungal derivatives of this therapeutic class.

  4. Drug

    IR501

    go.drugbank.com/drugs/DB06464
    Experimental

    It specifically targets autoreactive T-cells, reducing their activity. It was last known to be in phase III clinical trials.

  5. Drug

    Beta-D-Glucose

    go.drugbank.com/drugs/DB02379
    Investigational

    It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement.

  6. Drug

    Lucanthone

    go.drugbank.com/drugs/DB04967
    Investigational

    It is currently being tested as a radiation sensitizer. … One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46).

  7. Drug

    Formebolone

    go.drugbank.com/drugs/DB01569
    IllicitInvestigational

    It is on the list of substances prohibited by the Word Anti-Doping Agency, and is regularly screened for in athletes. … It has been used experimentally in the treatment of growth retardation, and has been noted to increase bone mass.

  8. Drug

    Vilzemetkib

    go.drugbank.com/drugs/DB21704
    Experimental

    The usage of the INN stem '-metkib' in the name indicates that Vilzemetkib is a MET (mesenchymal epithelial transition factor) kinase inhibitor.

  9. Drug

    Mubodina

    go.drugbank.com/drugs/DB17616
    Experimental

    It is a recombinant human minibody directed against complement component C5. … It was investigated in various conditions including primary membranoproliferative glomerulonephritis and typical hemolytic uremic syndrome.

  10. Drug

    PN0621

    go.drugbank.com/drugs/DB05218
    Experimental

    It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech.